Page 15 - Cipla

Cipla unit gets notice from US firm for termination of acquisition deal

In November 2018, Cipla had announced that InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

Sensex slips 207pts on late sell-off; Axis Bank sheds 6%, Bajaj Finance 5%

Stock market LIVE: Broader indices also trimmed gains at close; PSU banking shares were in demand, while private banking shares witnessed selling pressure

Stocks to Watch: Bajaj Auto, Axis Bank, ITC, Maruti, L&T, SBI Life, Cipla

The broader markets may swing to the global cues, while individual stocks are likely to react to corporate earnings and company specific developments in trade today

Cipla posts 7% year-on-year rise in Q2 PAT, riding on 10% revenue growth

Sequentially, however, the company has posted muted growth-revenue growth of 0.3%, and a PAT decline of 0.5%. Ebitda dipped sequentially too, by 9%

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

Cipla eyes acquisitions in India, US after Covid-led windfall

With a funding frenzy currently underway in India, Cipla may struggle to find attractive targets

Hold Nifty long with a stop at Tuesday's low, recommends Vinay Rajani

On the upside, the Nifty may face resistance in the range of 17,950-18,000, says the technical analyst from HDFC Securities

India growth, steady margins are key to near-term upsides for Cipla

Over the medium term, success of the new launches in the US would drive gains

Stocks to watch: M&M, Glenmark Life Sciences, Cipla, Adani Power, Tata Chem

Stocks from the banking, real estate and auto sectors will be in focus amid the RBI policy outcome later today

Cipla's Q1 PAT grows 24% to Rs 715 crore riding on domestic sales

The company posted a 27% YoY increase in income from operations, at Rs 5,504 cr. Ebitda grew 28% to Rs 1,346 cr with a resulting Ebitda margin of 24.5%

Top headlines: Govt buries retro tax; Cipla Q1 net profit rises 24%

Business Standard brings you the top headlines on Thursday

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Cipla, Dr Reddy's Labs: Tech charts show up to 11% upside in pharma stocks

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

Cipla hits new high on DCGI nod to import Moderna vaccine; up 4% in 2 days

At this stage, there is no definitive agreement on commercial supplies, the company said in response to media queries on vaccine import

Stocks to watch: Voda Idea, RIL, Cipla, Indiabulls Housing, pharma stocks

Vodafone Idea is likely to post a narrowing of losses in Q4FY21 even though subscriber losses and zero IUC regime may dent the top-line

Top headlines: Amazon battles regulators, e-way bill generation grows

Business Standard brings you the top headlines on Wednesday

Cipla gets DCGI nod to import Moderna vaccine; no commercial deal yet

1st mRNA vax part of US-India pact; no commercial deal yet

Five Indian drugmakers to jointly start trial of Merck & Co's Covid-19 drug

(Reuters) - Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

Nifty headed for upside target of 16,000: Vinay Rajani of HDFC Securities

Momentum indicators are in favour of bulls